Patents by Inventor Ulf Björklund

Ulf Björklund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230227456
    Abstract: The present invention relates to a solid oral composition comprising a crystalline form of Rabeximod or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable additive.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 20, 2023
    Inventor: Ulf Björklund
  • Publication number: 20230227455
    Abstract: The present invention relates to a process for preparing 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo-[2,3-b]quinoxaline, wherein said process is suitable for large scale synthesis.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 20, 2023
    Inventor: Ulf Björklund
  • Publication number: 20230131227
    Abstract: The present invention provides a pharmaceutical composition comprising a reversely thermo-reversible hydrogel as active ingredient, for administration to the eye of mammalian subjects. In particular, it relates to a pharmaceutical composition for use in, and a method for, the ophthalmic treatment of dry eye disease.
    Type: Application
    Filed: March 12, 2021
    Publication date: April 27, 2023
    Inventors: Martin VIDAEUS, Hans AGELAND, Ulf BJÖRKLUND, Gerhard GARHÖFER
  • Publication number: 20220133717
    Abstract: The present invention relates to therapeutic uses of compositions comprising 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo-[2,3-b]quinoxaline in the treatment of human subjects suffering from Rheumatoid Arthritis.
    Type: Application
    Filed: December 22, 2021
    Publication date: May 5, 2022
    Applicant: CYXONE AB
    Inventor: Ulf BJÖRKLUND
  • Patent number: 7589093
    Abstract: Novel substituted indoloquinoxalines of formula wherein R1 is hydrogen or represents one or more similar or different substituents in the positions 7 to 10 selected from the group halogen, lower alkyl/alkoxy, hydroxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, R2 represents similar or different C1-C4 alkyl substituents, X is CO or CH2, Y is OH, NH2, NH—(CH2)n—R3 wherein R3 represents lower alkyl, OH, NH2, NHR4 or NR5R6 wherein R4, R5 and R6 independently are lower alkyl or cyclo-alkyl and n is an integer of from 2 to 4, with the provision that when X is CH2, Y is OH or NH—(CH2)n—OH, and pharmacologically acceptable salts thereof are described. The compounds are useful as drugs for preventing and/or treating autoimmune diseases.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: September 15, 2009
    Assignee: Oxypharma AB
    Inventors: Jan Bergman, Robert Engqvist, Bengt Gerdin, Ingemar Kihlström, Ulf Björklund
  • Patent number: 7164885
    Abstract: Methods and techniques for selective service access are described. A short range, wireless device establishes lists of available devices within its transmitting proximity that are able to provide a desired service. The lists can be ranked based upon a service profile, e.g., established by the device user. The lists can also be periodically updated to accommodate device mobility.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: January 16, 2007
    Assignee: Telefonaktiebolaget L M Ericsson (publ)
    Inventors: Annika Jonsson, Ulf Björklund, Fergal Ladley